HEALTH | Biontech To Price Vaccine Below Market Rates, Differentiate Between Regions

MILAN | ITALY – – BioNTech, first in the race to produce evidence of a working COVID-19 vaccine, is planning to price the two-show regime below ‘typical market rates’ an would differentiate pricing between counties or regions.

Speaking at a Financial Times online event, the German biotech firm’s strategy head Ryan Richardson said the price tag of the vaccine, which is co-developed with Pfizer and which has yet to win regulatory approval, would the financial risks that its private-sector investors have incurred.

‘We’ve tried to pursue a balanced approach that recognize that innovation requires capital and investment so we plan to price our vaccine well below typical market rates reflecting the situation that we’re in and with the global to insure broad – based access around the world’, Richardson said at the FT event.

‘I expect there to be differential pricing in certain regions of the world’, he added, declining to elaborate on the different price tags.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s